WindMIL Therapeutics Announces Clinical Research Collaboration with Bristol-Myers Squibb to Evaluate Marrow-Infiltrating Lymp...
December 19 2019 - 7:00AM
WindMIL Therapeutics today announced it has entered into a new
clinical research collaboration with Bristol-Myers Squibb Company
(NYSE:BMY) to evaluate the safety and efficacy of WindMIL
Therapeutics’ marrow-infiltrating lymphocytes (MILs™) in
combination with Bristol-Myers Squibb’s nivolumab (Opdivo®), a
PD-1 immune checkpoint inhibitor, in patients with locally advanced
unresectable or metastatic non-small cell lung cancer (NSCLC) who
are refractory to, or have relapsed on, an anti-PD-1-containing
regimen.
This open-label, multi-center Phase 2a clinical trial will
assess the safety and efficacy of MILs alone and in combination
with nivolumab. MILs - NSCLC™ is an adoptive cell therapy product
produced via WindMIL’s proprietary process to activate and expand T
cells derived from the bone marrow of NSCLC patients. The first
three to six patients in this Phase 2a study will be treated with
MILs - NSCLC only. Following this, approximately 20 patients
will be treated with MILs - NSCLC plus nivolumab. The study’s
primary endpoint is objective response rate (ORR).
“WindMIL is pleased to announce this collaboration with BMS and
are excited to be evaluating MILs - NSCLC with nivolumab in
patients with non-small cell lung cancer,” said Don Hayden,
chairman and chief executive officer of WindMIL. “MILs have already
shown a favorable safety profile and encouraging efficacy in
patients with hematologic malignancies. Working together, we’re
committed to finding ways to address the unmet needs of patients
living with cancer.”
Under the terms of the agreement, WindMIL will be the sponsor of
the trial and Bristol-Myers Squibb will supply nivolumab for use in
the study.
About Marrow-Infiltrating Lymphocytes
(MILs™)Marrow-infiltrating lymphocytes (MILs™) are
developed through a proprietary process to activate and expand
memory T cells found in the bone marrow into MILs. Because memory T
cells in bone marrow occur as a result of the immune system’s
recognition of tumor antigens, MILs are specifically suited for
adoptive cellular immunotherapy and directly eradicate or
facilitate eradication of each patient’s unique cancer.
WindMIL is currently studying use of MILs to treat
patients with multiple myeloma, non-small cell lung
cancer, squamous cell carcinoma of the head and neck, and
glioblastoma, and plans to expand into other solid
tumors. To date, more than 100 patients have received treatment
with MILs and ongoing studies continue to build upon the favorable
safety profile and promising efficacy seen in early
development.
About WindMIL TherapeuticsWindMIL Therapeutics
is a clinical-stage company developing a novel class of autologous
cell therapies based on marrow infiltrating lymphocytes (MILs™) for
cancer immunotherapy. As the leader in cellular therapeutics
emanating from bone marrow, WindMIL translates novel insights in
bone marrow immunology into life-saving cancer immunotherapeutics
for patients. The company’s proprietary process to activate and
expand these cells offers unique immunotherapeutic advantages,
including inherent tumor-specificity, high cytotoxic potential and
long persistence. For more information, please visit:
https://windmiltx.com.
WindMIL Therapeutics Media Contact:Gina
Cestari6 Degrees(917) 797-7904gcestari@6degreespr.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2023 to Sep 2024